Advisory Panel Urges Randomized Trials For New Prostate Cancer Treatments
This article was originally published in The Gray Sheet
Developers of targeted prostate cancer treatments should conduct randomized clinical trials with "watchful waiting" as a control, according to FDA's Gastroenterology and Urology Devices panel
You may also be interested in...
Device marketing, patient preferences, physician bias and financial incentives can thwart attempts by comparative effectiveness researchers to randomize prostate cancer patients into clinical trials.
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.